PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
18.95%
Net income growth above 1.5x CRWV's 7.67%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-4.40%
Negative yoy D&A while CRWV is 26.15%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-36.18%
Negative yoy deferred tax while CRWV stands at 3.70%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
No Data
No Data available this quarter, please select a different quarter.
-232.16%
Both reduce yoy usage, with CRWV at -110.52%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-232.16%
Negative yoy usage while CRWV is 112.72%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
211.73%
Well above CRWV's 23.14%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-3.07%
Both yoy CFO lines are negative, with CRWV at -510.76%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-11.02%
Both yoy lines negative, with CRWV at -74.30%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
7.08%
Purchases growth of 7.08% while CRWV is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
27.15%
We have some liquidation growth while CRWV is negative at -100.00%. John Neff notes a short-term liquidity advantage if competitor is holding or restricted.
No Data
No Data available this quarter, please select a different quarter.
93.19%
We have mild expansions while CRWV is negative at -70.42%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
-46.93%
Negative yoy issuance while CRWV is 4.88%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
-7.19%
We cut yoy buybacks while CRWV is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.